share_log

Cantor Fitzgerald Reiterates Neutral on Sarepta Therapeutics, Maintains $128 Price Target

Benzinga ·  Feb 14 08:51

Cantor Fitzgerald analyst Kristen Kluska reiterates Sarepta Therapeutics (NASDAQ:SRPT) with a Neutral and maintains $128 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment